Propanc Biopharma, Common Stock Cash Flow From Operations
| PPCB Stock | USD 6.10 3.80 38.38% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Propanc Biopharma,'s long-term financial health and intrinsic value.
Propanc |
Propanc Biopharma, Common Company Cash Flow From Operations Analysis
Propanc Biopharma,'s Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Propanc Biopharma, Cash Flow From Operations | (1.44 M) |
Most of Propanc Biopharma,'s fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Propanc Biopharma, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Propanc Biopharma, Common has (1.44 Million) in Cash Flow From Operations. This is 100.27% lower than that of the Biotechnology sector and 102.3% lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 100.15% higher than that of the company.
Propanc Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Propanc Biopharma,'s direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Propanc Biopharma, could also be used in its relative valuation, which is a method of valuing Propanc Biopharma, by comparing valuation metrics of similar companies.Propanc Biopharma, is currently under evaluation in cash flow from operations category among its peers.
Propanc Fundamentals
| Return On Asset | -13.07 | |||
| Current Valuation | 1.53 M | |||
| Shares Outstanding | 1.76 B | |||
| Shares Owned By Insiders | 1.60 % | |||
| Price To Earning | (0.04) X | |||
| EBITDA | (2.14 M) | |||
| Net Income | (2.66 M) | |||
| Cash And Equivalents | 4.07 K | |||
| Total Debt | 1.1 M | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (1.44 M) | |||
| Earnings Per Share | (0.09) X | |||
| Target Price | 1.52 | |||
| Beta | 1.42 | |||
| Market Capitalization | 705.56 K | |||
| Total Asset | 81.65 K | |||
| Z Score | -85.8 | |||
| Net Asset | 81.65 K |
About Propanc Biopharma, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Propanc Biopharma, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Propanc Biopharma, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Propanc Biopharma, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Propanc Pink Sheet
Propanc Biopharma, financial ratios help investors to determine whether Propanc Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Propanc with respect to the benefits of owning Propanc Biopharma, security.